Boardroom Alpha
Start trial
10-K primary document
OSRH · Annual Report (Form 10-K) · Filed March 31, 2026

Osr Holdings Inc — 10-K exhibit

ea028315401ex10-35.htm
Osr Holdings Inc on Boardroom Alpha

Exhibit 10.35

 

THIRD AMENDMENT TO PROMISSORY NOTES

 

Reference is made to those certain promissory notes listed on Exhibit A hereto (each, a “Note” and, collectively, the “Notes”), between OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.), a Delaware corporation, and Bellevue Global Life Sciences Investors, LLC, a Delaware limited liability company.

 

1. Amendment of the Maturity Date. The parties hereto agree that Section 1 of each Note shall be amended and restated in its entirety as follows: “The Principal balance of this Note shall be payable by the Maker on December 31, 2026 (the “Maturity Date”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or stockholder of the Maker be obligated personally for any obligations or liabilities of the Maker hereunder.”

 

2. Binding Effect. Except as amended pursuant to paragraph 1 above, the Notes shall remain in full force and effect in accordance with their terms and are hereby ratified and confirmed by each of the parties hereto.

 

3. Counterparts. This amendment may be executed and delivered electronically and in counterparts, each of which will be deemed to be an original copy of this amendment and all of which, when taken together, will be deemed to constitute one and the same agreement.

 

[Signature page follows]

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this amendment to be duly executed as of the latest date set forth below.

 

  OSR HOLDINGS, INC.
  (f/k/a BELLEVUE LIFE SCIENCES
  ACQUISITION CORP.)
   
  By: /s/ Kuk Hyoun Hwang
  Name: Kuk Hyoun Hwang
  Title: Chief Executive Officer
  Date: 9/29/2025

 

  ACCEPTED AND AGREED:
   
  BELLEVUE GLOBAL LIFE SCIENCES INVESTORS, LLC
   
  BY: BELLEVUE CAPITAL MANAGEMENT LLC, ITS MANAGER
   
  By: /s/ Kuk Hyoun Hwang
  Name: Kuk Hyoun Hwang
  Title: Chief Executive Officer
  Date: 9/29/2025

 

[Signature page to Promissory Note Amendment]

 

 

 

Exhibit A Promissory Notes

 

1.Promissory Note, dated April 8, 2024, as amended on January 9, 2025 and January 23, 2025, between OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.) and Bellevue Global Life Sciences Investors, LLC.

 

2.Promissory Note, dated April 17, 2024, as amended on January 9, 2025 and January 23, 2025, between OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.) and Bellevue Global Life Sciences Investors, LLC.

 

3.Promissory Note, dated May 14, 2024, as amended on January 9, 2025 and January 23, 2025, between OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.) and Bellevue Global Life Sciences Investors, LLC.

 

4.Promissory Note, dated July 11, 2024, as amended on January 9, 2025 and January 23, 2025, between OSR Holdings, Inc. (f/k/a Bellevue Life Sciences Acquisition Corp.) and Bellevue Global Life Sciences Investors, LLC.

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer